Archive for the ‘Events’ Category
Waters Corporation Continues to Meet Today’s Challenges for Improved Laboratory Operations with New Products at Pittcon 2009
Last Updated on Friday, 13 March 2009 01:26 Written by Editor Friday, 13 March 2009 01:26
Waters Gives Scientists, Business and Laboratory Managers More of What They Want: Efficiency, Data Quality, Productivity and Profitability
CHICAGO, March 9 /PRNewswire-FirstCall/ — Against a backdrop of a worldwide economic recession, Waters Corporation (NYSE: WAT) is demonstrating how its industry-leading analytical instruments and informatics products address today’s greatest scientific and business challenges at the 60th Pittsburgh Conference (Pittcon) on Analytical Chemistry and Applied Spectroscopy, March 8 – 13, 2009.
“Pittcon 2009 promises to be like no other in its past simply because today, the stakes are higher,” said Dr. Rohit Khanna, Vice President of Worldwide Marketing, Waters Division. “In no uncertain terms, our customers are telling us they need to achieve more: more productivity, more efficiency, and more speed in all of their efforts. ACQUITY UPLC and Xevo MS systems, combined with Waters informatics and consumable chemistries, are responding to the full range of current laboratory challenges through unrivalled performance and proven reliability to truly redefine the analytical process.”
Waters’ headline offerings at Pittcon 2009 include the Xevo(TM) family of mass spectrometers, the Xevo TQ and Xevo QTof MS Systems, and an expanded suite of products for UltraPerformance LC(R) (UPLC(R)) aimed at bringing laboratories new levels of efficiencies. Additionally, Waters shares the spotlight with its latest technology addition, supercritical fluid chromatography (SFC), by featuring products from TharSFC at the exhibition.
Xevo Family of Mass Spectrometers – Bringing the Power of Advanced MS to More Scientists
With Xevo benchtop mass spectrometers, Waters is making advanced-performance MS more accessible than ever — regardless of who uses the instrument. Xevo mass spectrometers are designed around the philosophy of Engineered Simplicity(TM) which combines outstanding instrument performance with simplicity enabled by IntelliStart(TM) technology to allow scientists to convert data into business-critical knowledge faster and with greater assurance.
New to Pittcon this year, Waters(R) Xevo quadrupole time-of-flight (QTof) mass spectrometer (MS) is an exact mass MS/MS benchtop instrument that is the most sensitive benchtop QTof system ever developed. Paired with Waters ACQUITY(R) UPLC system, the Xevo QTof MS is the only commercially-available MS system to give scientists one-of-a-kind UPLC/MS(E) performance – a novel method of data acquisition that captures “all of the data all of the time” at unparalleled speeds to maximize the amount of information collected from minimal sample amounts.
Also new to Pittcon is the Waters Xevo TQ MS System, an advanced tandem quadrupole mass spectrometer that tackles the most demanding quantification applications for target compounds at low concentrations in highly complex and diverse samples. Waters Xevo TQ MS System is uniquely qualified to allow laboratories to conform to the new US Food and Drug Administration’s guidelines for bioanalytical method validation. The intent of the guidance is to prevent errors due to matrix effects made during the toxicological assessment of a target compound or its metabolites; errors than can have life-threatening consequences during clinical trials.
With the Xevo family of mass spectrometers, Waters is combining advanced performance with ease-of-use to answer the need for laboratories to get more out of their investment in analytical technology.
“According to our customers, the effects of the world’s economic, resource and globalization challenges are felt in the laboratories as much as any other part of an organization’s mission-critical operations,” said Brian Smith, Vice President of Mass Spectrometry Operations for the Waters Division. “These challenges put even greater burdens on labs to answer complex questions faster with greater confidence using fewer resources than ever before. Consequently, today’s laboratory technology should be measured on its ability to improve lab productivity and decision-making if our customers are to be successful.”
UPLC Technology – Changing the Analytical Laboratory Since 2004
Five years ago at Pittcon 2004, Waters sparked a wave of innovation in analytical chemistry when it introduced its ACQUITY UPLC System, an entirely new category of liquid chromatograph based on novel, patented sub two-micron chromatography particles that has transformed the analytical laboratory in many ways.
“The introduction of the Waters ACQUITY UPLC system in 2004 was more than an innovative product introduction, it spurred a revolution in high performance liquid chromatography,” remarks Larry Schmid, President, Strategic Directions International, Los Angeles, California, consultants and advisors to the analytical instrument industry and publishers of Instrument Business Outlook newsletter. “ACQUITY UPLC inspired most other major HPLC suppliers to develop similar systems that have changed the dynamics of liquid separation in the lab, especially in relation to mass spectrometry sample introduction. The ACQUITY UPLC and other so-called “fast LCs” provide greatly improved resolution and faster analysis, something laboratory scientists desperately needed. So five years on, the HPLC marketplace is now fundamentally different thanks to Waters’ groundbreaking product development effort.”
Since its introduction, Waters has installed thousands of UPLC systems, and the thousands of laboratories that have replaced HPLC with UPLC and as an inlet to mass spectrometers are enjoying the benefits.
“The speed that we’re getting is incredible and in our business, speed is money. We’re a production lab so we don’t have time to wait around or run samples overnight and pick up the results in the morning. Now I can run ACQUITY in one shift, get my results, and release the product–all in one day. This is a huge gain in productivity for us,” says Steve Lunetta, Manager, Quality Control Laboratory, PharmaVite LLC, San Fernando, California, the makers of Nature Made(R) brand vitamins and nutritional supplements.
A Newly Enhanced UPLC Product Portfolio
Marking the fifth anniversary of its launch, Waters has expanded its award-winning UPLC product portfolio and will have its entire complement of UPLC products on display during Pittcon 2009, March 8 – 13 in Chicago. They include the nanoACQUITY UPLC(R) system for life science applications; the PATROL(TM) UPLC Process analyzer, an at-line version for process monitoring; numerous compatible LC and quadrupole mass detectors; compatible high-performance triple, tandem, and quadrupole time-of-flight/ion mobility research-grade mass spectrometers; more than 50 column configurations and chemistries including newly-redeveloped ACQUITY UPLC columns, the result of Waters Designed for Six Sigma (DFSS) quality process; the TRIZAIC(TM) UPLC System with nanoTile(TM) Technology designed to deliver exceptional sensitivity for limited-sample, direct-flow, nanoscale protein separations; a new hand-held controller for managing system operations; and applications-specific UPLC/MS and UPLC/MS/MS system solutions for food safety, amino acid, intact protein, oligonucleotide, peptide, metabolite profiling, bioanalysis, impurity profiling, ADME screening, and proteomics analyses.
UPLC for At-Line Process Analysis
Designed with the same enabling technology platform as Waters ACQUITY UPLC System, PATROL UPLC Process Analyzer moves existing liquid chromatography (LC) analysis from off-line Quality Control (QC) laboratories directly to the manufacturing floor resulting in significant improvements in production efficiency with real-time analysis, reducing both process cycle times and assuring product quality.
At Pittcon 2009, Waters is introducing the PATROL UPLC Process Analyzer for at-line analysis to complement the on-line version introduced at Pittcon 2008.
Posted under Events, Press Releases, USA and Canada | Comments Off
Last Updated on Tuesday, 10 March 2009 12:24 Written by Editor Tuesday, 10 March 2009 12:24
CHICAGO – (Business Wire) Agilent Technologies Inc. (NYSE:A) today introduced major enhancements to its flagship gas chromatography (GC) line that enable users to run more samples and increase performance with challenging samples at lower cost. The second generation of Agilent’s HPLC-Chip/MS is also making its debut here, offering double the life of existing HPLC-Chips. In addition, Agilent announced a Cooperative Research and Development Agreement (CRADA) with the U.S. Environmental Protection Agency (EPA) to study perfluorinated compounds in the environment.“Analytical labs need to run more samples in less time without sacrificing quality, and Agilent has always responded with breakthrough GC designs,†said Shanya Kane, Agilent vice president and general manager, Gas Chromatography Systems and Workflow Automation. “Today we’re announcing just the latest examples of a long history of Agilent innovations helping GC customers maximize the value of their instrument investments.â€
Agilent Introduces 7693A Series GC Automated Liquid Sampler (ALS)
The 7693A ALS is a completely new design, offering substantial gains in throughput, flexibility, sample preparation automation and serviceability for all current Agilent benchtop GC models. The new ALS is modular, letting users configure the exact autosampler they need – starting from a basic injector with a 16-sample turret, and later adding capabilities as needs expand. Options include a second injection tower, a 150-vial sample tray and a vial heater/mixer/barcode reader for long unattended operation.
Agilent’s exclusive fast-injection technology is twice the speed of any competitive ALS. Injection time of less than 100 milliseconds minimizes sample degradation and the effects of needle discrimination. The two-injector configuration doubles sample throughput.
Agilent offers an optional Heater/Mixer/Barcode Reader module that can automate a number of pre-injection procedures. This offers substantial savings in time and labor, and operator-to-operator variability is eliminated. Solvent consumption and waste expense can be trimmed by as much as 90 percent.
New Multimode GC Inlet Delivers Higher Performance at Lower Cost
Agilent also introduced the Multimode GC inlet with split, splitless and programmable temperature vaporization (PTV) capability, costing approximately $2,500 less than the previous version and featuring much lower maintenance requirements.
Temperature programming capability facilitates a wide range of injection volumes, analysis of thermally unstable samples and better productivity through fewer sample-preparation steps. The new inlet incorporates Agilent’s Turn-Top feature, which allows liners to be changed in seconds without special tools or training.
A major benefit of PTV is the ability to inject high matrix samples with little or no cleanup into a GC or GC/MS. Productivity is enhanced and maintenance is further reduced when this is combined with the backflush function available with the Agilent 7890A GC and 5975C GC/MS.
“Dirty†samples can be injected into the GC or GC/MS. When the compounds of interest have reached the detector, gas flow is reversed in the precolumn, where the high boiling compounds are flushed out of it and the inlet before they reach the analytical column. The results are longer column life and reduced maintenance requirements. The new inlet shares common liners, septa, ferrules, nuts and o-rings with the standard inlet, eliminating the need to stock special parts.
World’s Most Inert Capillary GC Column Line Expanded
Agilent announced the addition of Agilent J&W DB-1ms and HP-1ms Ultra Inert columns to the industry’s most inert family of capillary GC columns, Agilent J&W Ultra Inert Capillary GC columns. The superior and consistent inertness of these columns allows for trace-level analysis of active compounds, such as acids and bases, with high confidence. This new chemistry is particularly well suited for applications such as fragrance fingerprinting, analysis of pesticides and drugs of abuse, and unknown sample screening.
“We’re raising the bar for GC column performance with reactive samples, and the excellent peak shapes these columns produce give our customers high confidence in the results,†said Helen Stimson, Agilent vice president and general manager, Consumables and Supplies Division.
Next-Generation HPLC-Chip for MS has Double the Life Expectancy
Agilent also unveiled the Agilent 1200 Series HPLC-Chip II, the second generation of its pioneering high-performance nano liquid chromatography/electrospray system for mass spectrometry. The new chip platform is designed to provide greater than two times the life of the original HPLC-Chip.
Agilent added proprietary Ion Implantation (II) technology to the new HPLC-Chips, extending life expectancy beyond 1,000 injections, depending on the application. The main benefits are lower cost-per-experiment and enhanced chip-to-chip and run-to-run reproducibility. The carbon ion implanted filter dramatically improves characteristics of polyimide surfaces as well as reduces friction between the rotary valve and the chip body for longer life.
Initially, the Agilent HPLC-Chip II is available in a phosphopeptide chip (for post-translational modifications), the large-capacity protein ID chip, and the ultra-high-capacity chip. HPLC-Chip II technology will be extended across the entire HPLC-Chip family in coming months. Agilent now offers 12 versions of HPLC-Chips, plus custom versions. All Agilent HPLC-Chips are compatible across the entire portfolio of Agilent mass spectrometers.
Agilent, U.S. EPA Collaborate to Study Perfluorinated Compounds
Agilent today announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Exposure Research Laboratory of the U.S. EPA to use the Agilent time-of-flight mass spectrometer (TOF-MS) to detect and identify both known and unknown perfluorinated compounds (PFCs) in the environment.
The study of perfluorinated organic compounds in the environment has increased recently as a result of continued studies that indicate their distribution, persistence and toxicity in the environment and biological systems. The collaborative efforts between the National Exposure Research Laboratory (NERL) and Agilent will focus on identifying PFOS and PFOA (perfluorooctanesulfonic acid and perfluorooctanoic acid – both used in a variety of commercial products) isomers and related compounds while characterizing their environmental distributions and the potential pathways for human exposure.
The Agilent 6220 Accurate Mass TOF used in this CRADA will help EPA detect and identify compounds in part-per-trillion range. This capability, along with Agilent MassHunter software, is well suited for detecting and identifying very small amounts of unknown compounds.
Posted under Events, Industry News, Press Releases, USA and Canada | Comments Off
Flavor/Fragrance Ingredients in the Works
Last Updated on Tuesday, 10 March 2009 12:21 Written by Editor Tuesday, 10 March 2009 12:21
DORTMUND, Germany and MILAN—The joint research efforts of InterMed Discovery (IMD) and Axxam SpA have resulted in a technology platform that offers screening solutions and the discovery of natural bioactive compounds valuable to companies in the food, beverages, flavor and fragrance industries.
Based on that success, the companies signed a second joint research agreement that will focus on discovery and validation of flavor/fragrance functional ingredients, which will then be offered to food, beverages, flavor and fragrance companies. The proprietary compounds will have clearly defined activity profiles and naturally derived chemical properties.
“This cooperation is a direct response to what we see as growing market needs,†said Dr. Thomas Henkel, managing director of InterMed Discovery. “Our innovative approach to developing natural functional ingredients together with Axxam caters perfectly to the increasing market demand for turnkey solutions.â€
Posted under Europe, Europe, Events, New Products, North America, Press Releases, Research Projects, USA and Canada | Comments Off
Zenobia Therapeutics, Inc. Announces Sale of Commercial Fragment Library Ideal for Crystallographic, NMR and SPR Screening
Last Updated on Tuesday, 3 March 2009 03:53 Written by Editor Tuesday, 3 March 2009 03:53
LA JOLLA, Calif., March 2 /PRNewswire/ — Zenobia Therapeutics, Inc. (Zenobia) the leader in fragment-based lead discovery (FBLD) for CNS diseases, announced today that they are adding a 352 compound fragment library to their product offerings. The library is ready for screening by X-ray, NMR, and SPR methods, contains soluble, verified protein binders, is shape and functionally diverse, and has an average molecular weight of 155 Da. The compounds are pre-plated and will initially cost ~ $11/compound. The library was constructed by Zenobia’s team of seasoned FBLD professionals with over 25 years combined experience. Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia, reported the first fragment-based crystallographic screening method in 2000.
“Over the past decade, FBLD has become a successful drug discovery method that has produced many NCEs and clinical candidates. We want FBLD to continue to positively impact drug discovery and are now providing a solid, simple starting point for fragment-based screening campaigns,” said Dr. Nienaber. “A great deal of the chemical space of drug-like molecules can be covered by a well chosen set of small fragment compounds. This efficient library design will provide researchers with a lot of information on target site binding within a small number of experiments,” said John Badger, Ph.D., Director of Structural Biology. The library has been examined by Dr. Ruo Steensma, Ph.D., Director of Chemistry for Zenobia Therapeutics. Dr. Steensma took forward two programs to IND using FBLD during her tenure as Director of Medicinal Chemistry at SGX Pharmaceuticals. “This is a perfect starting point for scientists interested in FBLD. The compounds are simple and ideally suited as starting points for further analoging. We look forward to working with fellow scientists who are interested in getting quality leads through this approach,” said Dr. Steensma. Co-founder of Zenobia, Robert Meadows, Ph.D., a co-inventor of the SAR by NMR method who has designed multiple fragment libraries for the NMR screening method says, “Zenobia’s library is a small, cherry picked selection of diverse chemotypes and shapes. And, since the compounds are all very soluble, screening with different methods is straightforward. Most importantly, once you find a hit with this library, developing the SAR is fast and economical.” Through consulting or collaborations, Zenobia offers its expertise in advancing SAR around fragment hits.
Posted under Discoveries, Innovations and Patents, Events, Industry News, Press Releases, USA and Canada | Comments Off
Prous Institute Presents Innovative Approach to Drug Discovery
Last Updated on Tuesday, 3 March 2009 03:44 Written by Editor Tuesday, 3 March 2009 03:44
BARCELONA, February 26 /PRNewswire/ — Prous Institute for Biomedical Research today presented its strategies for drug discovery on its newly designed website (http://www.prousresearch.com). A large computational project with basic research support and broad disease coverage is being developed at Prous Institute under the broad-based Epistemic Drug Discovery(R) project.
President and C.E.O. of the Institute, Dr. J.R. Prous, explained that “We are committed to accelerating biomedical knowledge by the synchronization of powerful expert knowledge-based systems and basic research. This next-generation drug R&D force is expected to increase the efficiency and efficacy of core drug R&D processes, facilitating continuous innovation.”
Two main drug discovery programs are being developed at the Institute. One is focused on the design, synthesis and biological evaluation of new small-molecule modulators of autophagy as therapeutic agents for cancer and neurodegeneration (Alzheimer’s disease and Huntington’s disease). Another program looks at target-driven drug discovery from natural sources, covering type 2 diabetes, psychological stress and asthma. The Institute’s computational tools enable the in silico screening of thousands of natural products in a rapid, reliable and cost-effective manner, as well as the discovery of new targets and new uses for existing drugs.
J.R. Prous commented “our approach is bringing us closer to drug discovery, and the Institute expects to have several compounds in preclinical evaluation by the end of this year (2009).”
Posted under Drug Development, Europe, Europe, Events, News by Region, News by Subject, North America, Press Releases | Comments Off
BioFocus DPI Extends Drug Discovery Collaboration with Lilly Drug Discovery & Development
Last Updated on Wednesday, 25 February 2009 11:56 Written by Editor Wednesday, 25 February 2009 11:56
BioFocus DPI has extended its drug discovery agreement with Eli Lilly and Company until end 2009. Under the terms of the agreement, BioFocus DPI will identify active compounds by screening of Lilly’s library compounds.
The agreement extension announced today builds on the successful collaboration begun in March 2005. BioFocus DPI has been working with Lilly on discovering new compounds that target specific cellular signal transduction pathways. With this agreement, Lilly secures continued access to BioFocus DPI’s screening and biology expertise to identify new potential target compounds.
‘We are pleased to extend this collaboration with Lilly into its fourth year,’ said Dr. Chris Newton, Senior VP, BioFocus DPI. ‘It is satisfying to know that BioFocus DPI’s drug discovery research consistently meets the standards of large pharma companies such as Lilly and that we are successful in these long term collaborative relationships.’
Posted under Biotech & Pharma Law, Cell Analysis, Cell-based Assays, Discoveries, Innovations and Patents, Events, Industry News, News by Region, North America, Press Releases, USA and Canada | Comments Off
European Molecular Biology Laboratory (EMBL) Signs Agreement to License Themis and Surflex-Dock Technologies from Tripos
Last Updated on Wednesday, 18 February 2009 04:13 Written by Editor Wednesday, 18 February 2009 04:13
ST. LOUIS, Mo.–(BUSINESS WIRE)–Triposâ„¢, a leading provider of drug discovery informatics products and services, today announced an agreement with the European Molecular Biology Laboratory (EMBL), Europe’s leading research institution for molecular biology, to license Tripos’ Themisâ„¢ and Surflex-Dockâ„¢ software to support their efforts in Chemical Biology. According to Dr. Joe Lewis, Head of the Chemical Biology Core Facility, a collaboration between EMBL, the DKFZ [German Cancer Research Center, Heidelberg] and the University of Heidelberg to provide the infrastructure and expertise to enable small molecule development to research groups at these institutions. “Anytime we can reduce the amount of time it takes to advance our drug discovery efforts, we are very pleased. Tripos’ Surflex-Dock, and new Themis product have enabled us to do exactly that.â€
In a benchmark study at EMBL, Surflex-Dock was installed on EMBL’s Linux Grid of 1,400 CPUs. Five million structures of EMBL’s virtual database of commercially available compounds were then docked into a binding site of a project’s receptor structure. The computation was completed in about two days and yielded a promising pool of candidates for experimental testing.
“Virtual screening has become a key technique in Chemical Biology to identify small molecules as tool compounds to help address biological questions. Our testing of Surflex-Dock’s capabilities in this area convinced us that its high speed and accuracy will enable us to quickly find the most promising compounds,†said Dr. Lewis.
Dr. Lewis added, “In first experiments performed at EMBL, Tripos’ Themis already provided interesting new chemical ideas contributing to new drug discovery projects, so in parallel, the Themis technology will enable us to search vast chemical fragment space, as composed and implemented into the Themis database by our medicinal chemists.â€
“The decision by the European Molecular Biology Laboratory to select our new Themis technology together with Surflex-Dock is very significant,†said Jim Hopkins, Tripos’ Chief Executive Officer. He added, “The vigorous EMBL study demonstrated that the powerful combination of these two Tripos offerings can effectively enhance the success of discovery efforts.â€
Posted under Business and Investment, Collaborations, Drug Development, Drug-Like Compounds, Europe, Events, Press Releases, USA and Canada | Comments Off
Pittcon 2009 Exposition Expected to Showcase Latest Innovations
Last Updated on Tuesday, 17 February 2009 03:08 Written by Editor Tuesday, 17 February 2009 03:08
Pittsburgh, PA, USA – The Pittcon 2009 Exposition, which takes place March 8-13, McCormick Place South, Chicago, Illinois will showcase 1,000Â exhibitors that manufacture, distribute, and market products for laboratory science and offer turn key services and solutions to laboratories in the industrial, academic, and government sectors. The Exposition will highlight the latest analytical and spectroscopic technologies and innovations for areas including, but not limited to bioanalytical chemistry, pharmaceutical science and drug discovery chemistry, nanotechnology, environmental analysis, forensics, food analysis, and homeland security.
The Exposition is international in scope with approximately 19% of the exhibiting companies headquartered in a variety of countries including Australia, Austria, Canada, China, France, Germany, Italy, Japan, Netherlands, and the United Kingdom. The 673,000 square foot exposition floor will include 2,244 booths, 43 seminar rooms, 2 complimentary mixers, and 4 specialized areas-New Exhibitor, Life Sciences, Laboratory Informatics, and the Green Corner, which is new this year, features exhibitors who offer environmental-friendly products and services. This year, Pittcon will be welcoming 122 new exhibitors which can be viewed at www.pittcon.org.
When asked to comment about the value of the Pittcon 2009 Exposition to conferees, Exposition Chairman Penny Gardner replied, “We believe Pittcon is a unique opportunity for conferees, as well as exhibitors, because it offers such a valuable learning experience.   It is the ideal venue to get a look at all the latest equipment, network with suppliers, interact with technical personnel, and make new vendor contacts-all in one place.”
Posted under Events, North America, Press Releases, USA and Canada | Comments Off
Protected: BIT’s 4th Annual Congress of International Drug Discovery Science & Technology 2006 (IDDST-2006)
Last Updated on Monday, 10 April 2006 07:53 Written by iddst2006 Wednesday, 15 February 2006 11:14
Posted under Africa, Asia, Asia, Business and Investment, Cancer Research, Collaborations, Discoveries, Innovations and Patents, Drug-Like Compounds, Education, Europe, Events, HIV Research, Industry News, Medicinal Chemistry, New Products, News by Subject, North America, Press Releases, Reagents, South America | Comments Off
MARCUS EVANS LIFE SCIENCES SUMMITS: UPCOMING EVENTS FOR 2006
Last Updated on Wednesday, 30 November 2005 03:06 Written by admin Wednesday, 30 November 2005 03:06
The Leading Events for the European Pharmaceutical Industry
NICOSIA, Cyprus. – 25 Nov. 2005 – marcus evans announces that the Life Sciences Summits 2006 will include the following areas: Drug Discovery, Clinical Trials, Manufacturing and Marketing.
World-renowned experts and senior executives from leading pharmaceutical companies will address the most relevant and impacting issues faced by corporations at this time.
A select group of innovative solution providers will meet with senior pharmaceutical executives to discuss vital industry issues in a variety of fields.
“The marcus evans Life Sciences Summits focus on providing the latest information in Drug Discovery, Clinical Trials, Manufacturing and Marketing. Our programmes are renowned for their quality and the real, tangible benefits they provide to all participants. Our goal is always to create the foremost event for Europe‘s leading pharmaceutical executives.†John Farry, General Manager Europe
About marcus evans Life Sciences Summits
marcus evans Life Sciences Summits deliver the highest quality events tailored to meet the demands of an evolving industry, responding to the industry players’ most pressing needs. Designed to meet the requirements of senior market representatives, our Life Sciences Summits are a unique opportunity to gain knowledge from undisputed experts while having the opportunity to network in a very interactive and stimulating environment.
Upcoming Summits:
ManuPharma – 3rd Annual Pharmaceutical Manufacturing Summit
27 – 29 March 2006
Raffles Le Montreux Palace, Montreux, Switzerland
www.manupharmaeurope.com
Discovery – 6th Annual Drug Discovery Summit
10 – 12 April 2006
The Monte-Carlo Bay Hotel and Resorts, Monaco
www.discovery-summit.com
PharmaBrand – 3rd Annual Pharmaceutical Marketing Summit
30 May – 1 June 2006
Hotel Hermitage, Monaco
www.pharmabrandeurope.com
Evolution – 5th Annual Clinical Trials Summit
23 – 25 October 2006
The Monte-Carlo Bay Hotel and Resorts, Monaco
www.evolution-summit.com
About marcus evans
marcus evans, one of the worlds leading business information companies is dedicated to the provision of global business intelligence and information to assist in strategic and effective decision making. marcus evans products include business and economic summits, high-level conferences, industry congresses, professional training and sports hospitality. The company employs over 3,000 staff in 54 global offices. marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.
Characters: 2,702
Words: 380
Lines: 63
For more information, please contact:
Sabah Khennouf – Georgiou
marcusevans
PO Box 24797
CY-1304 Nicosia
tel: +357 22 849314
fax: +357 22 849307
SabahK@marcusevanscy.com
www.marcusevans.com
Posted under Europe, Europe, Events, Press Releases | Comments Off
BioSpace Launches 5th Edition Of BioCapitalâ„¢ Hotbed Campaign For Mid-Atlantic’s Life Science Industry
Last Updated on Monday, 13 June 2005 04:42 Written by admin Thursday, 12 May 2005 04:47
NAPLES, FL, May 12, 2005 – BioSpace, the leading online information source for the biotechnology and pharmaceutical industries, unveiled last night the 5th edition of the BioCapital Hotbed Campaign during a special reception at PharmaDiscovery 2005 Conference & Exhibition at the Washington, D.C. Convention Center.
2005 BioCapital Hotbed Map
http://www.biospace.com/hotbed/9/biocapital_map.cfm
2005 BioCapital Hotbed Homepage:
http://www.biospace.com/hotbed.cfm?RegionID=9
In addition to PharmaDiscovery 2005, BioSpace partnered with Maryland Biotechnology Association (MdBio), Northern Virginia Technology Council (NVTC), Technology Council of Maryland (TCM) and Virginia Biotechnology Association (VaBio) to promote and highlight the rich life science industry in the states of Delaware, Maryland, Virginia and Washington, D.C.
“We are pleased to be supporting BioSpace’s mission and the BioCapital campaign. BioCapital’s partnerships with professionals from within the biotechnology and pharmaceutical industries and PharmaDiscovery’s strong focus on the vital challenges affecting drug discovery productivity in those industries, makes for a unique and mutually beneficial relationship,” said Kevin Richards, Vice President, Life Sciences, Reed Exhibitions.
The 5th edition of BioCapital showcases a variety of biopharmaceutical companies located within the Mid-Atlantic region including AstraZeneca, Celera, Gene Logic and Wyeth. Other companies participating in the campaign include technology service providers PPD Development and Medifacts International. The BioCapital Hotbed map also highlights research institutes, non-profit organizations and universities within the area.
“BioSpace is grateful for all of the support we have received from the various organizations and members of the Mid-Atlantic life science community. We would also like to thank the participants of the 2005 campaign, especially PharmaDiscovery, who have made the 5th edition of BioCapital a huge success,” said Brian Vacanti, Division Manager, BioSpace.
The campaign features a BioCapital Hotbed Map, created by BioSpace’s professional artist, which displays the corporate logos and facilities of participating organizations. Copies of the map are available through BioSpace. The map is further enhanced through the integration of many functional components including a BioCapital Hotbed Homepage, on BioSpace’s industry leading Website, BioSpace.com.
The original 1985 Biotech Bayâ„¢ Map for the San Francisco Bay Area hangs on permanent display in the Smithsonian Institution’s National Museum of American History. BioCapital was first launched in 1996.
About BioSpace
BioSpace is globally recognized as the leading provider of web-based resources and information to the life science industry. For 20 years BioSpace has helped to accelerate communication and discovery among business and scientific leaders in the biopharmaceutical market. With a well-established site infrastructure and loyal online audience of over 1.5 million unique monthly visitors, BioSpace.com offers an unparalleled distribution channel for recruitment, investment, product, event and other life science industry messages.
BioSpace promotes and adds online functionality to distinct regional clusters of bioscience industry through their world renowned Hotbed Campaigns. Current campaigns include BioCorridorâ„¢, Biotech Bayâ„¢, BioGardenâ„¢, Pharm Countryâ„¢ and others. Additionally, BioSpace offers an online life science career center, live career events and a clinical trials database, CCISâ„¢.
BioSpace, a Career Innovations company, is headquartered in Naples, FL.
Related companies:
Accelovance, American Type Culture Collection, American University, Arkios BioDevelopment International, AstraZeneca Pharmaceuticals LP, Australian Trade Commission (Austrade), Baxter BioScience Corporation MD, BioSpace, Celera Genomics Group-an Applera Corp. Business, Delaware State University, EMINENT, Services Corporation, EntreMed Inc., Gene Logic Inc., George Washington University, Georgetown University, Human Genome Sciences Inc., Johns Hopkins University, Kforce Professional Staffing, MdBio Inc., Medifacts, International, MedImmune Inc., Montgomery College, New Jersey Biotechnology and Life Sciences Coalition, Northern Virginia Technology Council (NVTC), Otsuka America Pharmaceutical Inc., PPD Piedmont Research, Center, Quest Pharmaceutical Services, Reed Exhibition Companies, SAIC-Frederick Inc., Southern Research Institute, Tech Council of Maryland, Timtec Inc., Towson University, University of Baltimore, University of Delaware, University of Maryland, University of Virginia, Virginia Biotechnology Association, Virginia State University, Virginia Tech, Wyeth (Richmond VA)
Posted under Events, North America, USA and Canada | Comments Off
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory